Skip to Content

CVS: Underappreciated and Undervalued

CVS: Underappreciated and Undervalued

Vishnu Lekraj: Over the last handful of years there has been a major trend within the healthcare services space between the major conglomerates that occupy their supply chain. Currently we have CVS looking to purchase Aetna, and we have Cigna merging with Express Scripts. We believe these two deals are significant and could provide significant returns for investors over the longer term. These key pieces of the healthcare services supply chain will combine into one company that will provide several services on several different fronts from major constituencies within the healthcare space.

Right now, we'd like to highlight the CVS-Aetna merger as being a key piece of the strategy or key piece of this trend. We believe the new company will be a very powerful player as it will combine retail pharmacy, PBM, and health insurance into one company. We believe the invested capital returns will be significantly above the weighted average cost of capital for this company moving forward, and as a result, we believe CVS is underappreciated and undervalued at the moment.

More in Stocks

About the Author

Vishnu Lekraj

Senior Equity Analyst
More from Author

Vishnu Lekraj is a senior equity analyst for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. He covers the healthcare services industry.

Lekraj joined Morningstar in 2008 after receiving a master’s degree in business administration from the University of Florida’s Hough Graduate School of Business. Before business school, he was a financial analyst for HSBC bank.

Lekraj holds a bachelor’s degree in finance from the Warrington College of Business Administration at the University of Florida, where he graduated summa cum laude. He is also a member of the Beta Gamma Sigma international honor society. In 2012, Lekraj ranked first in the professional services industry in the StarMine Analyst Awards, presented by the Financial Times.

Sponsor Center